FANCD2 and head and neck cancer: To characterize the genetic dependencies of an FA-deficient versus WT genetic background, we used CRISPR-Cas9 to engineer a FA deficiency (FANCD2-null) in a well-characterized head and neck cancer cell line (FaDu) (Supplementary Fig. S1).